Fundamental Analysis of SCISPARC LTD(NASDAQ:SPRC) stock

Fundamental Rating

Overall SPRC gets a fundamental rating of 1 out of 10. We evaluated SPRC against 193 industry peers in the Pharmaceuticals industry. SPRC has a bad profitability rating. Also its financial health evaluation is rather negative. SPRC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

SPRC had negative earnings in the past year.

In the past year SPRC has reported a negative cash flow from operations.

SPRC had negative earnings in each of the past 5 years.

SPRC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SPRC has a worse Return On Assets (-46.15%) than 61.58% of its industry peers.

With a Return On Equity value of -67.77%, SPRC perfoms like the industry average, outperforming 49.47% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-46.15%
ROE	-67.77%
ROIC	N/A

ROA(3y)-42.86%

ROA(5y)-136.21%

ROE(3y)-59.52%

ROE(5y)-9664.38%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SPRC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SPRC does not have a ROIC to compare to the WACC, probably because it is not profitable.

SPRC has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, SPRC has less shares outstanding

SPRC has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -7.29, we must say that SPRC is in the distress zone and has some risk of bankruptcy.

SPRC has a Altman-Z score of -7.29. This is in the lower half of the industry: SPRC underperforms 67.37% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that SPRC is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.00, SPRC is in line with its industry, outperforming 59.47% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.29

ROIC/WACCN/A

WACC9.52%

2.3 Liquidity

A Current Ratio of 4.10 indicates that SPRC has no problem at all paying its short term obligations.

SPRC has a Current ratio of 4.10. This is comparable to the rest of the industry: SPRC outperforms 59.47% of its industry peers.

A Quick Ratio of 3.63 indicates that SPRC has no problem at all paying its short term obligations.

SPRC has a Quick ratio (3.63) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.1
Quick Ratio	3.63

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SPRC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.22%, which is quite impressive.

Looking at the last year, SPRC shows a very strong growth in Revenue. The Revenue has grown by 113.26%.

EPS 1Y (TTM)36.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-163.64%

Revenue 1Y (TTM)113.26%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SPRC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SPRC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SCISPARC LTD

NASDAQ:SPRC (12/20/2024, 8:00:02 PM)

After market: 0.219 +0.01 (+2.67%)

0.2133

0 (-0.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners1.33%

Inst Owner Change0%

Ins Owners0%

Ins Owner ChangeN/A

Market Cap2.21M

AnalystsN/A

Price TargetN/A

Short Float %0.93%

Short Ratio0.14

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.29
P/tB	0.5
EV/EBITDA	N/A

EPS(TTM)-0.81

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.57

FCFYN/A

OCF(TTM)-0.57

OCFYN/A

SpS0

BVpS0.73

TBVpS0.43

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-46.15%
ROE	-67.77%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-42.86%

ROA(5y)-136.21%

ROE(3y)-59.52%

ROE(5y)-9664.38%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.1
Quick Ratio	3.63
Altman-Z	-7.29

F-Score3

WACC9.52%

ROIC/WACCN/A

Cap/Depr(3y)898.83%

Cap/Depr(5y)539.3%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)36.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-163.64%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)113.26%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y15.5%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y53.97%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y25.67%

OCF growth 3YN/A

OCF growth 5YN/A

SCISPARC LTD (SPRC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens